Brainstorm Cell Therapeutics Inc (BCLI) USD0.00005
Sell:$0.96Buy:$0.99
$0.06
(5.98%)
- This stock can be held in a
Stocks and Shares ISA$0.06
(5.98%)$0.06
(5.98%)Company Information
About this company
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Key people
Key facts
- EPICBCLI
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS10501E3009
- Market cap$6.36m
- Employees27
- Shares in issue6.52m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.